Treatment of Obsessive-Compulsive and Related Disorders
Tóm tắt
Pharmacotherapy and cognitive-behavioural therapy (CBT) have been studied in many of the obsessive-compulsive and related disorders (OCRDs). Serotonin reuptake inhibitors (SRIs) and cognitive-behavioural therapies (CBT) are first-line considerations in many, but not all, of these conditions. There are fewer data available on the combination of these treatment modalities in OCRDs. In obsessive-compulsive disorder (OCD), the SRIs and CBT – which include exposure and response prevention (ERP) – are well-established safe and efficacious first-line treatments in adult and paediatric populations. While various pharmacotherapy augmentation strategies have been studied, the most evidence-based approach to date is augmentation with antipsychotic agents. There is also evidence of the value of CBT in the management of treatment-refractory patients. A number of SRIs, such as clomipramine and fluoxetine, have shown efficacy in randomized controlled trials of the pharmacotherapy of body dysmorphic disorder (BDD). There are relatively few data on pharmacotherapy augmentation approaches in BDD. CBT has also been found efficacious in a number of psychotherapy trials of BDD. Less is known about the optimal treatment of the other OCRDs, i.e., hoarding disorder (HD), trichotillomania (hair-pulling disorder, or HPD), and excoriation (skin-picking) disorder (SPD). While patients with HD may have been included in RCTs on OCD, no data from randomized controlled trials of pharmacotherapy specifically for HD have been reported. There is some support for the value of CBT in HD. In HPD, controlled trials of olanzapine, N-acetyl cysteine (NAC), and clomipramine (vs. desipramine) have provided evidence of efficacy. There also is evidence supporting the efficacy of behaviour therapy in reducing hair-pulling. Results from randomized controlled trials of SRIs in SPD have been mixed, with some agents such as fluoxetine and citalopram demonstrating improvement on certain measures of picking behaviour. Behaviour therapy also appears to be useful for SPD.
Tài liệu tham khảo
Freud S. Character and anal erotism. In: Strachey J, editor. Standard edition of the complete psychological works of Sigmund Freud. London’ Hogarth Press; 1908. p. 169-75.
Stein DJ, Stone MH. Essential papers on obsessive-compulsive disorders. New York: New York University Press; 1997.
American Psychiatric Association. DSM-5: diagnostic and statistical manual of mental disorders. Washington DC: American Psychiatric Publishing; 2013.
American Psychiatric Association. American Psychiatric Association diagnostic and statistical manual of mental disorders 4th edition - text revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000.
Stein DJ. Psychobiology of anxiety disorders and obsessive-compulsive spectrum disorders. CNS Spectr. 2008;13:23–8.
Soomro GM, Altman D, Rajagopal S, Oakley-Browne M. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev. 2008;CD001765.
Fineberg NA, Reghunandanan S, Brown A, Pampaloni I. Pharmacotherapy of obsessive-compulsive disorder: evidence-based treatment and beyond. Aust NZ J Psychiatry. 2013;47:121–41. This manuscript provides a comprehensive literature review of the evidence supporting available strategies for the pharmacological treatment of OCD.
Ackerman DL, Greenland S. Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. J Clin Psychopharmacol. 2002;22:309–17.
Fineberg NA, Gale TM. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2005;8:107–29.
National Institute for Health and Clinical Excellence. Obsessive-compulsive disorder: core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder. London: National Institute for Health and Clinical Excellence; 2005.
Teng EJ, Woods DW, Twohig MP. Habit reversal as a treatment for chronic skin picking: a pilot investigation. Behav Modif. 2006;30:411–22.
Bloch MH, McGuire J, Landeros-Weisenberger A, Leckman JF, Pittenger C. Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Mol Psychiatry. 2010;15:850–5.
Greist JH, Jefferson JW, Kobak KA, Chouinard G, DuBoff E, Halaris A, et al. A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 1995;10:57–65.
Katz RJ, DeVeaugh-Geiss J, Landau P. Clomipramine in obsessive-compulsive disorder. Biol Psychiatry. 1990;28:401–14.
Tollefson GD, Birkett M, Koran L, Genduso L. Continuation treatment of OCD: double-blind and open-label experience with fluoxetine. J Clin Psychiatry. 1994;55(Suppl):69–76.
Donovan MR, Glue P, Kolluri S, Emir B. Comparative efficacy of antidepressants in preventing relapse in anxiety disorders - a meta-analysis. J Affect Disord. 2010;123:9–16.
Goodman WK, McDougle CJ, Barr LC, Aronson SC, Price LH. Biological approaches to treatment-resistant obsessive compulsive disorder. J Clin Psychiatry. 1993;54(Suppl):16–26.
Dold M, Aigner M, Lanzenberger R, Kasper S. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol. 2013;16:557–74. This article provides a systematic literature review of all double-blind randomized placebo-controlled trials investigating the efficacy of antipsychotic augmentation of SRIs in treatment-resistant OCD.
Soltani F, Sayyah M, Feizy F, Malayeri A, Siahpoosh A, Motlagh I. A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder. Hum Psychopharmacol. 2010;25:509–13.
Askari N, Moin M, Sanati M, Tajdini M, Hosseini SM, Modabbernia A, et al. Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. CNS Drugs. 2012;26:883–92.
Mowla A, Khajeian AM, Sahraian A, Chohedri AH, Kashkoli F. Topiramate augmentation in resistant OCD: a double-blind placebo-controlled clinical trial. CNS Spectr. 2010;15:613–7.
Berlin HA, Koran LM, Jenike MA, Shapira NA, Chaplin W, Pallanti S, et al. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2011;72:716–21.
Bruno A, Mico U, Pandolfo G, Mallamace D, Abenavoli E, Di NF, et al. Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Psychopharmacol. 2012;26:1456–62.
Bloch MH, Wasylink S, Landeros-Weisenberger A, Panza KE, Billingslea E, Leckman JF, et al. Effects of ketamine in treatment-refractory obsessive-compulsive disorder. Biol Psychiatry. 2012;72:964–70.
Rodriguez CI, Kegeles LS, Levinson A, Feng T, Marcus SM, Vermes D, et al. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology. 2013;38:2475–83.
Hollander E, Allen A, Kwon J, Aronowitz B, Schmeidler J, Wong C, et al. Clomipramine vs desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Arch Gen Psychiatry. 1999;56:1033–9.
Phillips KA, Albertini RS, Rasmussen SA. A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Arch Gen Psychiatry. 2002;59:381–8.
Perugi G, Giannotti D, Di VS, Frare F, Saettoni M, Cassano GB. Fluvoxamine in the treatment of body dysmorphic disorder (dysmorphophobia). Int Clin Psychopharmacol. 1996;11:247–54.
Phillips KA, Dwight MM, McElroy SL. Efficacy and safety of fluvoxamine in body dysmorphic disorder. J Clin Psychiatry. 1998;59:165–71.
Phillips KA. An open-label study of escitalopram in body dysmorphic disorder. Int Clin Psychopharmacol. 2006;21:177–9.
Phillips KA, Najjar F. An open-label study of citalopram in body dysmorphic disorder. J Clin Psychiatry. 2003;64:715–20.
Allen A, Hadley SJ, Kaplan A, Simeon D, Friedberg J, Priday L, et al. An open-label trial of venlafaxine in body dysmorphic disorder. [Abstracts], 28. 2003. Spain, Sixth International Obsessive Compulsive Disorder Conference. Conference Proceeding.
Phillips KA, Menard W. A prospective pilot study of levetiracetam for body dysmorphic disorder. CNS Spectr. 2009;14:252–60.
Phillips KA. The broken mirror: understanding and treating body dysmorphic disorder. New York: Oxford University Press; 1996.
Phillips KA, Hollander E. Treating body dysmorphic disorder with medication: evidence, misconceptions, and a suggested approach. Body Image. 2008;5:13–27.
Bloch MH, Landeros-Weisenberger A, Dombrowski P, Kelmendi B, Wegner R, Nudel J, et al. Systematic review: pharmacological and behavioral treatment for trichotillomania. Biol Psychiatry. 2007;62:839–46.
Swedo SE, Leonard HL, Rapoport JL, Lenane MC, Goldberger EL, Cheslow DL. A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). N Engl J Med. 1989;321:497–501.
Van Ameringen M, Mancini C, Patterson B, Bennett M, Oakman J. A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. J Clin Psychiatry. 2010;71:1336–43.
Grant JE, Odlaug BL, Kim SW. N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2009;66:756–63.
Bloch MH, Panza KE, Grant JE, Pittenger C, Leckman JF. N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. J Am Acad Child Adolesc Psychiatry. 2013;52:231–40.
Grant JE, Odlaug BL, Chamberlain SR, Keuthen NJ, Lochner C, Stein DJ. Skin picking disorder. Am J Psychiatry. 2012;169:1143–9. Here the authors provide a timeous comprehensive review of SPD, a condition that is a new addition to DSM-5. The authors recommend several management approaches to SPD, based on clinical experience and research findings.
Bloch MR, Elliott M, Thompson H, Koran LM. Fluoxetine in pathologic skin-picking: open-label and double-blind results. Psychosomatics. 2001;42:314–9.
Simeon D, Stein DJ, Gross S, Islam N, Schmeidler J, Hollander E. A double-blind trial of fluoxetine in pathologic skin picking. J Clin Psychiatry. 1997;58:341–7.
Arbabi M, Farnia V, Balighi K, Mohammadi MR, Nejati-Safa AA, Yazdchi H, et al. Efficacy of citalopram in treatment of pathological skin picking: a randomized double blind placebo controlled trial. Acta Med Iran. 2008;46:367–72.
Keuthen NJ, Jameson M, Loh R, Deckersbach T, Wilhelm S, Dougherty DD. Open-label escitalopram treatment for pathological skin picking. Int Clin Psychopharmacol. 2007;22:268–74.
Rosa-Alcázar AI, Sánchez-Meca J, Gómez-Conesa A, Marin-Martínez F. Psychological treatment of obsessive-compulsive disorder: a meta-analysis. Clin Psychol Rev. 2008;28:1310–25.
Simpson HB, Foa EB, Liebowitz MR, Ledley DR, Huppert JD, Cahill S, et al. A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder. Am J Psychiatry. 2008;165:621–30.
Cottraux J, Mollard E, Bouvard M, Marks I. Exposure therapy, fluvoxamine, or combination treatment in obsessive-compulsive disorder: one-year followup. Psychiatry Res. 1993;49:63–75.
Hohagen F, Winkelmann G, Rasche-Rüchle H, Hand I, König A, Münchau N, et al. Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Results of a multicentre study. Br J Psychiatry Suppl. 1998;71–8.
Storch EA, Murphy TK, Goodman WK, Geffken GR, Lewin AB, Henin A, et al. A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry. 2010;68:1073–6.
Wilhelm S, Buhlmann U, Tolin DF, Meunier SA, Pearlson GD, Reese HE, et al. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry. 2008;165:335–41.
Kushner MG, Kim SW, Donahue C, Thuras P, Adson D, Kotlyar M, et al. D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry. 2007;62:835–8.
Phillips KA. Understanding body dysmorphic disorder: an essential guide. New York: Oxford University Press; 2009.
Veale D, Gournay K, Dryden W, Boocock A, Shah F, Willson R, et al. Body dysmorphic disorder: a cognitive behavioural model and pilot randomised controlled trial. Behav Res Ther. 1996;34:717–29.
Rosen JC, Reiter J, Orosan P. Cognitive-behavioral body image therapy for body dysmorphic disorder. J Consult Clin Psychol. 1995;63:263–9.
Cermele JA, Melendez-Pallitto L, Pandina GJ. Intervention in compulsive hoarding. A case study. Behav Modif. 2001;25:214–32.
Hartl TL, Frost RO. Cognitive-behavioral treatment of compulsive hoarding: a multiple baseline experimental case study. Behav Res Ther. 1999;37:451–61.
Saxena S, Maidment KM, Vapnik T, Golden G, Rishwain T, Rosen RM, et al. Obsessive-compulsive hoarding: symptom severity and response to multimodal treatment. J Clin Psychiatry 2002;21-7.
Tolin DF, Frost RO, Steketee G. An open trial of cognitive-behavioral therapy for compulsive hoarding. Behav Res Ther. 2007;45:1461–70.
Steketee G, Frost RO, Tolin DF, Rasmussen J, Brown TA. Waitlist-controlled trial of cognitive behavior therapy for hoarding disorder. Depress Anxiety. 2010;27:476–84.
Gilliam CM, Norberg MM, Villavicencio A, Morrison S, Hannan SE, Tolin DF. Group cognitive-behavioral therapy for hoarding disorder: an open trial. Behav Res Ther. 2011;49:802–7.
Muroff J, Steketee G, Frost RO, Tolin DF. Cognitive behavior therapy for hoarding disorder: Follow-up findings and predictors of outcome. Depress Anxiety 2013. This paper provides information on the efficacy of CBT over the longer run in hoarding disorder, a new addition to DSM.
Steketee G, Frost RO, Wincze J, Greene K, Douglass H. Group and individual treatment of compulsive hoarding: a pilot study. Behav Cogn Psychother. 2000;28:259–68.
Saxena S. Pharmacotherapy of compulsive hoarding. J Clin Psychol. 2011;67:477–84. The author has reviewed the studies of the effects of hoarding on response to SRI medications in patients with OCD, as well as recent studies of pharmacotherapy specifically for patients with hoarding disorder, a new addition to DSM.
Flessner CA, Penzel F, Board TLC-SA, et al. Current treatment practices for children and adults with trichotillomania: consensus among experts. Cogn Behav Pract. 2010;17:290–300.
Chamberlain SR, Odlaug BL, Boulougouris V, Fineberg NA, Grant JE. Trichotillomania: neurobiology and treatment. Neurosci Biobehav Rev. 2009;33:831–42.
Woods DW, Wetterneck CT, Flessner CA. A controlled evaluation of acceptance and commitment therapy plus habit reversal for trichotillomania. Behav Res Ther. 2006;44:639–56.
Ninan PT, Rothbaum BO, Marsteller FA, Knight BT, Eccard MB. A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. J Clin Psychiatry. 2000;61:47–50.
van Minnen A, Hoogduin KA, Keijsers GP, Hellenbrand I, Hendriks GJ. Treatment of trichotillomania with behavioral therapy or fluoxetine: a randomized, waiting-list controlled study. Arch Gen Psychiatry. 2003;60:517–22.
Dougherty DD, Loh R, Jenike MA, Keuthen NJ. Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both? J Clin Psychiatry. 2006;67:1086–92.
Siev J, Reese HE, Timpano K, Wilhelm S. Assessment and treatment of pathological skin picking. In: Grant JE, Potenza MN, editors. The Oxford handbook of impulse control disorders. Oxford: Oxford University Press; 2012. p. 360–74.
Schuck K, Keijsers GP, Rinck M. The effects of brief cognitive-behaviour therapy for pathological skin picking: a randomized comparison to wait-list control. Behav Res Ther. 2011;49:11–7. This study is one of two RCTs in SPD and thus contributes significantly to the relatively scant evidence based literature on psychotherapy for skin-picking disorder (SPD).
Alonso P, Pujol J, Cardoner N, Benlloch L, Deus J, Menchón JM, et al. Right prefrontal repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2001;158:1143–5.
Blomstedt P, Sjöberg RL, Hansson M, Bodlund O, Hariz MI. Deep brain stimulation in the treatment of obsessive-compulsive disorder. World Neurosurg. 2013;80:e245–53. This is the first comprehensive literature review of deep brain stimulation (DBS) which has in recent years emerged as a treatment for severe cases of therapy-refractory OCD.
de Koning PP, Figee M, van den Munckhof P, Schuurman PR, Denys D. Current status of deep brain stimulation for obsessive-compulsive disorder: a clinical review of different targets. Curr Psychiatry Rep. 2011;13:274–82.
Greenberg BD, Rauch SL, Haber SN. Invasive circuitry-based neurotherapeutics: stereotactic ablation and deep brain stimulation for OCD. Neuropsychopharmacology. 2010;35:317–36.